Healius Limited (HLS.AX)

AUD 1.53

(1.33%)

Market Cap (In AUD)

1.1 Billion

Revenue (In AUD)

1.74 Billion

Net Income (In AUD)

-645.8 Million

Avg. Volume

2.33 Million

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.08-1.86
PE
-1.59
EPS
-0.96
Beta Value
0.743
ISIN
AU0000033359
CUSIP
Q4548G107
CIK
-
Shares
726133000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Paul D. Anderson B.Com., C.A.
Employee Count
-
Website
https://www.healius.com.au
Ipo Date
1998-08-03
Details
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through four segments: Pathology, Imaging, Day Hospitals, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. It operates 2,105 pathology sites; 11 day hospital sites; and 134 imaging sites. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.